Zentalis Pharmaceuticals Inc. said it has entered into a clinical collaboration agreement with GlaxoSmithKline PLC.
Zentalis said it will evaluate the combination of ZN-c3, an oral WEE1 inhibitor product candidate, and Zejula niraparib, GlaxoSmithKline's polymerase PARP inhibitor, in patients with advanced epithelial ovarian cancer.
Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies.
Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study, with GlaxoSmithKline providing all required doses of niraparib. Zentalis will maintain full ownership of ZN-c3.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.